16 out 59 cases (27.1%) and 10 out 59 cases (16.9%) of HER2 IHC scores of 2+ and 3+ breast cancer cases were scored with moderate 2+ and strong 3+ HMGCR, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.